These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
749 related articles for article (PubMed ID: 26191267)
1. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma. Li H; Wang Y; Su F; Li J; Gong P Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267 [TBL] [Abstract][Full Text] [Related]
2. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients. Pan JB; Hou YH; Zhang GJ Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939 [TBL] [Abstract][Full Text] [Related]
3. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065 [TBL] [Abstract][Full Text] [Related]
4. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080 [TBL] [Abstract][Full Text] [Related]
5. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608 [TBL] [Abstract][Full Text] [Related]
6. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638 [TBL] [Abstract][Full Text] [Related]
7. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317 [TBL] [Abstract][Full Text] [Related]
8. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Shan L; Wang Z; Guo L; Sun H; Qiu T; Ling Y; Li W; Li L; Liu X; Zheng B; Lu N; Ying J Lung Cancer; 2015 Sep; 89(3):337-42. PubMed ID: 26141217 [TBL] [Abstract][Full Text] [Related]
9. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455 [TBL] [Abstract][Full Text] [Related]
10. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status. Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125 [TBL] [Abstract][Full Text] [Related]
11. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083 [TBL] [Abstract][Full Text] [Related]
13. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Nose N; Uramoto H; Iwata T; Hanagiri T; Yasumoto K Lung Cancer; 2011 Mar; 71(3):350-5. PubMed ID: 20615575 [TBL] [Abstract][Full Text] [Related]
14. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441 [TBL] [Abstract][Full Text] [Related]
15. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173 [TBL] [Abstract][Full Text] [Related]
16. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients. Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633 [TBL] [Abstract][Full Text] [Related]
18. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712 [TBL] [Abstract][Full Text] [Related]
20. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Chiu CH; Ho HL; Doong H; Yeh YC; Chen MY; Chou TY; Tsai CM Oncotarget; 2015 Apr; 6(10):8407-17. PubMed ID: 25823662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]